Valuation: Addex Therapeutics Ltd

Market Cap 6.62M 8.18M 7.19M 6.19M 11.61M 772M 11.83M 79.46M 30.78M 381M 30.73M 30.06M 1.32B P/E 2024
0.8x
P/E 2025 -0.88x
Enterprise Value 5.02M 6.2M 5.45M 4.69M 8.8M 585M 8.96M 60.22M 23.32M 288M 23.29M 22.78M 1B EV / Sales 2024
5.67x
EV / Sales 2025 28.1x
Free-Float
43.94%
Yield 2024 *
-
Yield 2025 -
1 day-2.68%
1 week-5.22%
Current month-5.22%
1 month-8.02%
3 months+14.14%
6 months-21.86%
Current year-21.30%
1 week 0.04
Extreme 0.04
0.05
1 month 0.04
Extreme 0.04
0.05
Current year 0.03
Extreme 0.0336
0.06
1 year 0.03
Extreme 0.0336
0.08
3 years 0.03
Extreme 0.0336
0.26
5 years 0.03
Extreme 0.0336
1.63
10 years 0.03
Extreme 0.0336
4
Manager TitleAgeSince
Chief Executive Officer 58 2013-05-31
Director of Finance/CFO 40 2017-05-31
Chief Tech/Sci/R&D Officer 69 2016-11-27
Director TitleAgeSince
Chairman 77 -
Director/Board Member 58 2014-12-31
Director/Board Member 81 2010-05-11
Date Insider Type Main position Quantity % Market Cap.
03-17Other

Founder

20,218,775 9.2469%
03-17Other

Chairman

3,009,585 1.3764%
03-17Other

Chief Financial Officer

602,908 0.2757%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%-5.22%-26.35%-59.63% 8.18M
-0.58%+7.28%-5.01%+2.53% 46.36B
+4.95%+9.31%+363.86%+598.16% 37.88B
+0.44%+11.12%+17.47%-12.91% 31.12B
-0.64%+1.92%+3.08%+53.58% 30.61B
+0.23%-0.29%+13.24%+21.10% 24.69B
+9.90%+13.32% - - 16.25B
+1.40%+12.99%+67.11%+132.76% 14.85B
+0.06%+9.28%+12.26%+21.70% 13.58B
+2.38%+5.69%+95.85%+97.63% 12.95B
Average +1.55%+7.48%+60.17%+94.99% 22.83B
Weighted average by Cap. +1.64%+8.01%+79.79%+132.35%

Financials

2024 2025
Net sales 410K 507K 445K 383K 719K 47.81M 732K 4.92M 1.91M 23.57M 1.9M 1.86M 81.9M 173K 214K 188K 162K 303K 20.15M 309K 2.07M 803K 9.94M 802K 785K 34.53M
Net income 7.06M 8.72M 7.66M 6.6M 12.37M 823M 12.6M 84.66M 32.79M 406M 32.74M 32.02M 1.41B -6.73M -8.31M -7.3M -6.29M -11.8M -784M -12.02M -80.73M -31.27M -387M -31.22M -30.54M -1.34B
Net Debt -3.3M -4.08M -3.58M -3.09M -5.79M -385M -5.89M -39.59M -15.33M -190M -15.31M -14.98M -659M -1.6M -1.98M -1.74M -1.5M -2.81M -187M -2.86M -19.24M -7.45M -92.18M -7.44M -7.28M -320M
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Employees
3
Date Price Change Volume
26-06-26 CHF 0.0436 -2.68% 7,633
26-06-25 CHF 0.0448 +6.67% 448,197
26-06-24 CHF 0.0420 -7.89% 20,001
26-06-23 CHF 0.0456 +5.07% 30,305
26-06-22 CHF 0.0434 -5.65% 181,002
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADXN Stock